GlaxoSmithKline Pakistan Limited has reported its financial results for the nine months ended September 30, 2026, showcasing growth in revenue and profit metrics compared to the previous year.
- Reporting Period: Nine months ended September 30, 2026 (un-audited)
- Revenue: PKR 48,113.40M (+8.8% YoY)
- Gross Profit: PKR 18,406.38M (+15.6% YoY)
- Operating Profit: PKR 12,121.83M (+15.7% YoY)
- Net Profit (PAT): PKR 7,191.11M (+15.4% YoY)
- EPS: PKR 22.58 (+15.4% YoY)
- Cash dividend: Nil
- Bonus shares: Nil
- Main driver: Improved gross margins and operational efficiencies contributed to the profit growth.